The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Study Type
EXPANDED_ACCESS
Talquetamab will be administered subcutaneously (SC).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.